As mentioned above, the clinical trial with the combination of crizotinib (ALK inhibitor) and nivolumab (PD-1 inhibitor) was terminated due to safety concerns in NSCLC, while the same combination of compounds showed an improved antitumor response with favorable side-effect tolerability in the in vivo model. The gene discussed is ALK; the disease is non-small cell lung carcinoma.